Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia Interventions: Biological: QH103 Cell Injection; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Conditions: B-cell Acute Lymphoblastic Leukemia Interventions: Biological: QH103 Cell Injection; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Conditions: B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Intervention: Drug: Blinatumomab Sponsor: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Conditions: B Precursor Acute Lymphoblastic Leukemia; Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Interventions: Drug: Blinatumomab Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission Intervention: Drug: Bortezomib Sponsors: Instituto do Cancer do Estado de São Paulo; Libbs Farmacêutica LTDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials